Tyra Biosciences is set to present a late-breaking oral presentation on the preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors harboring activating FGFR3 mutations or fusions. The data will be shared at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) in Barcelona, Spain.
The presentation, titled "Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)," will be part of the Late Breaking Abstracts and Proffered Papers session, highlighting novel discoveries in drug development.
SURF301 Trial Details
The SURF301 trial is a multicenter, open-label Phase 1/2 study evaluating TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations. In addition to the oral presentation, Tyra Biosciences will also present two posters detailing the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of TYRA-300 from the SURF301 study, alongside a Trials-in-Progress poster from SURF301.
About TYRA-300
TYRA-300 is an oral, FGFR3-selective inhibitor designed to target and inhibit the activity of FGFR3, a receptor tyrosine kinase that plays a role in cell growth and differentiation. Aberrant FGFR3 signaling, resulting from genetic mutations or fusions, has been implicated in the development and progression of various cancers, including urothelial carcinoma and other solid tumors.
Tyra Biosciences is leveraging its in-house precision medicine platform, SNÅP, to develop next-generation precision medicines targeting FGFR biology. The company's focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions.
